TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01103232

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Experimental group
Description: Electrical muscle stimulation (EMS) of the right wrist flexor muscles was applied. EMS was applied for 20 minutes. Maximum current intensity tolerated was used so as to stimulate the highest possible number of motor unit. The stimulation intensity increased every five minutes during a session. Electrical stimulation was applied for thirty sessions (one session a day, five days a week for six weeks.)
Study: NCT01831414

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Water immersion at cervical level
Description: balneotherapy session of spinal cord patients with a Water immersion at cervical level

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Water immersion at xyphoid level
Description: balneotherapy session of spinal cord patients with a Water immersion at xyphoid level
Study: NCT04547426

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Wine with or without alcohol and snuff with or without nicotine
Description: Two by two factorial of wine and snuff with meals

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Wine with or without alcohol and snuff with or without nicotine
Description: Two by two factorial of wine and snuff with meals

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Wine with or without alcohol and snuff with or without nicotine
Description: Two by two factorial of wine and snuff with meals

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Wine with or without alcohol and snuff with or without nicotine
Description: Two by two factorial of wine and snuff with meals
Study: NCT00127413

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy - Pain
Description: Pain treatment

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy-Integrated
Description: Integrated treatment

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Processing Therapy - PTSD
Description: Cognitive processing therapy

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Treat as Usual
Description: Treatment as usual
Study: NCT01049061

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MORAb-003
Description: MORAb-003 is intravenously administered to patients with solid tumor once a week for 4 weeks as 1 cycle in order to investigate dose-limiting toxicity and estimate maximum tolerated dose
Study: NCT02934516

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Cesarean section
Description: Abdominal disimpaction with lower uterine segment support: the edge of the lower uterine segment is grasped by 3-4 modified Allies forceps (with broader jaws) applied along the lower edge of the incision until it is completely supported. These forceps are handled by the assistant, and gentle traction is applied upward, perpendicular to the uterine surface and away from the fetal head without excessive force. Accordingly, the hand of the surgeon could be inserted into the uterine cavity, and adequate space for manipulations is available without applying pressure on the lower segment. The fetal head is eventually grasped and delivered.~Classic push method: delivering the head with assistance by pushing the fetal head vaginally

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cesarean section
Description: Abdominal disimpaction with lower uterine segment support: the edge of the lower uterine segment is grasped by 3-4 modified Allies forceps (with broader jaws) applied along the lower edge of the incision until it is completely supported. These forceps are handled by the assistant, and gentle traction is applied upward, perpendicular to the uterine surface and away from the fetal head without excessive force. Accordingly, the hand of the surgeon could be inserted into the uterine cavity, and adequate space for manipulations is available without applying pressure on the lower segment. The fetal head is eventually grasped and delivered.~Classic push method: delivering the head with assistance by pushing the fetal head vaginally
Study: NCT04140890

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Habit Formation
Description: Treatment sessions consist of 12 weekly health coaching sessions at participants' home. During the intervention period, an occupational therapist will help the participant to commit to developing new simple habits (dietary habits or physical activity habits) in each 60-minute session.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Education
Description: In the education group, participants will receive newsletters containing general healthy aging materials over 12 weeks. A trained research assistant will call participants to verify receipt of the newsletter, and answer their questions about the materials. Each phone call will last \~15 minutes.
Study: NCT00618462

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive behavioral therapy (CBT)
Description: CBT will include weekly 50-minute sessions for 8 weeks. The sessions will focus on learning skills to cope with urges to gamble and developing alternatives to gambling.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive behavioral therapy (CBT)
Description: CBT will include weekly 50-minute sessions for 8 weeks. The sessions will focus on learning skills to cope with urges to gamble and developing alternatives to gambling.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Contingency management (CM)
Description: CM will provide incentive, such as a gift certificate to a store or restaurant, for completing activities not related to gambling. Participants and their therapists will decide upon two potential alternative activities to gambling during each therapy session.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Psychoeducation therapy
Description: Psychoeducation therapy will include weekly 50-minute therapy sessions for 8 weeks. The sessions will focus on education about gambling and related problems.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Case management
Description: Case management will assist participants in obtaining additional services from the community as needed.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Gamblers Anonymous (GA)
Description: All participants will be referred to GA, a support group of people who are recovering from gambling addiction, and will be encouraged to attend meetings.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Gamblers Anonymous (GA)
Description: All participants will be referred to GA, a support group of people who are recovering from gambling addiction, and will be encouraged to attend meetings.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Gamblers Anonymous (GA)
Description: All participants will be referred to GA, a support group of people who are recovering from gambling addiction, and will be encouraged to attend meetings.
Study: NCT00822315

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: efavirenz
Description: tenofovir 245 mg / lamivudine 300 mg / efavirenz 600 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: raltegravir
Description: tenofovir 245 mg / lamivudine 300 mg / raltegravir 400 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: raltegravir
Description: tenofovir 245 mg / lamivudine 300 mg / raltegravir 800 mg
Study: NCT01778062

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Indacaterol
Description: Indacaterol 150µg once daily oral inhalation

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: Placebo once daily oral inhalation
Study: NCT01715623

Intervention type: BIOLOGICAL
Intervention: a blood sample
Description: Dosage of Ig

Intervention type: BIOLOGICAL
Intervention: a blood sample
Description: Dosage of Ig

Intervention type: BIOLOGICAL
Intervention: a blood sample
Description: Dosage of Ig

Intervention type: BIOLOGICAL
Intervention: a blood sample
Description: Dosage of Ig
Study: NCT01054196

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lenalidomide
Description: daily dose dependent on dose-escalation schedule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: melphalan
Description: 100 mg/m2 given Days -2 and -1
Study: NCT00003458

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antineoplaston therapy (Atengenal + Astugenal)
Description: Children with a brain tumor will receive Antineoplaston therapy (Atengenal + Astugenal).
Study: NCT01474837

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intervention: Exercise and motivational interviewing
Description: 12 sessions of exercise with MI
Study: NCT02834572

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: All About Me
Description: Assessment and algorithm to determine recommended HIV testing approach

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: HIV testing information
Study: NCT00050089

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: No Antiretroviral Drug-Free Period (No ARDFP) vs ARDFP
Description: Continuation or interruption of ART treatment

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard ART vs Mega ART
Description: Standard therapy vs Intensified therapy

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: No Antiretroviral Drug-Free Period (No ARDFP) vs ARDFP
Description: Continuation or interruption of ART treatment

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard ART vs Mega ART
Description: Standard therapy vs Intensified therapy

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: No Antiretroviral Drug-Free Period (No ARDFP) vs ARDFP
Description: Continuation or interruption of ART treatment

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard ART vs Mega ART
Description: Standard therapy vs Intensified therapy

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: No Antiretroviral Drug-Free Period (No ARDFP) vs ARDFP
Description: Continuation or interruption of ART treatment
Study: NCT01103232

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Control group
Description: Conventional mode of transcutaneous electrical nerve stimulation (TENS) was applied for the control subjects. TENS was applied for 20 minutes. The stimulus intensity was adjusted as the lowest current at which the subject felt only a slight tickling of the impulses. A visible, and palpable muscle contraction was not provided during TENS stimulation. The stimulus intensity was not changed during the first session. Subsequently, TENS was applied at same intensity in all sessions. TENS was applied for thirty sessions (one session a day, five days a week for six weeks).
Study: NCT02145169

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Inhaled Nitrous Oxide
Description: Patients undergoing procedural sedation with Ketamine will receive inhaled Nitrous Oxide
Study: NCT01670071

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paliperidone extended-release
Description: Patients will receive 6 mg to 12 mg of paliperidone extended-release tablet once daily orally.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Risperidone immediate-release
Description: Patients will receive 3 mg to 7 mg of risperidone immediate-release tablet orally.
Study: NCT03796000

Intervention type: PROCEDURE
Intervention: tissue samples, blood and stool sample
Description: Tissue samples from gastroscopy/colonoscopy.
Study: NCT01059019

Intervention type: DIETARY_SUPPLEMENT
Group type: SHAM_COMPARATOR
Intervention: Omega-3 Fatty Acid Supplements
Description: Twenty patients labeled as group A (Control Group) will not receive the omega-3 supplement. The Control Group will be treated in the same standard professional way as our normal refractive patients, while another 20 patients labeled as group B (Treatment group) will be given omega- 3 supplements 1 capsule 3 x a day for 2 weeks pre op and 1 month post op plus the regular post op medications. From these supplements, this will be equivalent to 750 mg of omega 3 fatty acids (both EPH and DHA), 1000 mg of Flaxseed oil, and about 183 IU of vitamin E per day. Patients will be asking to follow up postoperatively after 2 days, 4 days, 1 week, 3 months and 6 months

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Omega-3 Fatty Acid Supplements
Description: Twenty patients labeled as group A (Control Group) will not receive the omega-3 supplement. The Control Group will be treated in the same standard professional way as our normal refractive patients, while another 20 patients labeled as group B (Treatment group) will be given omega- 3 supplements 1 capsule 3 x a day for 2 weeks pre op and 1 month post op plus the regular post op medications. From these supplements, this will be equivalent to 750 mg of omega 3 fatty acids (both EPH and DHA), 1000 mg of Flaxseed oil, and about 183 IU of vitamin E per day. Patients will be asking to follow up postoperatively after 2 days, 4 days, 1 week, 3 months and 6 months
Study: NCT04202536

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Besifovir Dipivoxil Maleate
Description: Besifovir 150 mg q.d. + L-carnitine (L-Carn Tab. 330 mg) 660 mg q.d. Other Name: Besifovir®

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tenofovir disoproxil fumarate(TDF)
Description: 300 mg tablet administered orally once daily Other Name: VIREAD®
Study: NCT03796000

Intervention type: PROCEDURE
Intervention: tissue samples, blood and stool sample
Description: Tissue samples from gastroscopy/colonoscopy.

Intervention type: PROCEDURE
Intervention: tissue samples, blood and stool sample
Description: Tissue samples from gastroscopy/colonoscopy.

Intervention type: PROCEDURE
Intervention: tissue samples, blood and stool sample
Description: Tissue samples from gastroscopy/colonoscopy.

Intervention type: PROCEDURE
Intervention: tissue samples, blood and stool sample
Description: Tissue samples from gastroscopy/colonoscopy.

Intervention type: PROCEDURE
Intervention: tissue samples, blood and stool sample
Description: Tissue samples from gastroscopy/colonoscopy.
Study: NCT01263054

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TransDiscal System
Description: Surgical Procedure using the TransDiscal System to perform disc biacuplasty.

Intervention type: OTHER
Group type: OTHER
Intervention: Medical Management
Description: Standard medical management, physical therapy, and lifestyle changes.
Study: NCT01158989

Intervention type: DEVICE
Intervention: PillCam
Description: Within four days of hospital admission, qualifying critically ill patients were assigned to the study and received a gastro-jejunal tube and one PillCam video telemetry capsule (Given Imaging Ltd., Yoqneam, Israel). In each critical care patient, placement of the video capsule was coupled with the placement of the medically necessary feeding tube. A flexible endoscope was inserted into the patient's mouth, and then advanced into the esophagus, stomach, and upper small intestine. The capsule was placed into a capsule delivery device and released into the distal duodenum after it had passed beyond the sight of the scope; a wire was placed to facilitate passage of the feeding tube. An abdominal X-ray was obtained to confirm feeding tube tip placement.

Intervention type: DEVICE
Intervention: PillCam
Description: Within four days of hospital admission, qualifying critically ill patients were assigned to the study and received a gastro-jejunal tube and one PillCam video telemetry capsule (Given Imaging Ltd., Yoqneam, Israel). In each critical care patient, placement of the video capsule was coupled with the placement of the medically necessary feeding tube. A flexible endoscope was inserted into the patient's mouth, and then advanced into the esophagus, stomach, and upper small intestine. The capsule was placed into a capsule delivery device and released into the distal duodenum after it had passed beyond the sight of the scope; a wire was placed to facilitate passage of the feeding tube. An abdominal X-ray was obtained to confirm feeding tube tip placement.
Study: NCT01760447

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo to sitagliptin plus metformin XR
Description: Participants received 2 tablets daily, both taken together with a meal. Each tablet contained placebo to sitagliptin plus metformin XR.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Metformin XR
Description: Participants received 2 tablets daily, both taken together with a meal, to provide a total daily dose of 1000 mg, 1500 mg or 2000 mg of metformin XR. Dosage was based on each participant's daily metformin dose prior to enrollment.
Study: NCT04350931

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: intradermal injection of BCG Vaccine
Description: 0.10 mL intradermal injection of BCG Vaccine over the distal insertion of the deltoid muscle onto the humerus (approximately one third down the left upper arm) slowly over 10 seconds
Study: NCT01390350

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Canakinumab
Description: 150mg subcutaneous injections on day 0

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 150mg subcutaneous injections on day 0
Study: NCT04618380

Intervention type: DIAGNOSTIC_TEST
Intervention: bUD-VA,bUN-RA, bUI-RA, bUI-CPS, bUN-CPS, contrast sensitivity
Description: The following clinical indexes are evaluated:~1. Binocular uncorrected distant visual acuity (bUD-VA) using the Greek version of the Early Treatment Diabetic Retinopathy Study Chart at four meters distance~2. Binocular uncorrected reading acuity at 60cm (bUI-RA) and at 40cm (bUN-RA), and~3. Binocular uncorrected critical print size at 60cm (bUI-CPS) and at 40cm (bUN-CPS).~All near and intermediate vision parameters are obtained using the Democritus Digital Acuity Reading Test (DDART), which is based on the Greek version of MNREAD.~Contrast sensitivity are evaluated with the Pelli-Robson test.

Intervention type: DIAGNOSTIC_TEST
Intervention: bUD-VA,bUN-RA, bUI-RA, bUI-CPS, bUN-CPS, contrast sensitivity
Description: The following clinical indexes are evaluated:~1. Binocular uncorrected distant visual acuity (bUD-VA) using the Greek version of the Early Treatment Diabetic Retinopathy Study Chart at four meters distance~2. Binocular uncorrected reading acuity at 60cm (bUI-RA) and at 40cm (bUN-RA), and~3. Binocular uncorrected critical print size at 60cm (bUI-CPS) and at 40cm (bUN-CPS).~All near and intermediate vision parameters are obtained using the Democritus Digital Acuity Reading Test (DDART), which is based on the Greek version of MNREAD.~Contrast sensitivity are evaluated with the Pelli-Robson test.

Intervention type: DIAGNOSTIC_TEST
Intervention: bUD-VA,bUN-RA, bUI-RA, bUI-CPS, bUN-CPS, contrast sensitivity
Description: The following clinical indexes are evaluated:~1. Binocular uncorrected distant visual acuity (bUD-VA) using the Greek version of the Early Treatment Diabetic Retinopathy Study Chart at four meters distance~2. Binocular uncorrected reading acuity at 60cm (bUI-RA) and at 40cm (bUN-RA), and~3. Binocular uncorrected critical print size at 60cm (bUI-CPS) and at 40cm (bUN-CPS).~All near and intermediate vision parameters are obtained using the Democritus Digital Acuity Reading Test (DDART), which is based on the Greek version of MNREAD.~Contrast sensitivity are evaluated with the Pelli-Robson test.

Intervention type: DIAGNOSTIC_TEST
Intervention: bUD-VA,bUN-RA, bUI-RA, bUI-CPS, bUN-CPS, contrast sensitivity
Description: The following clinical indexes are evaluated:~1. Binocular uncorrected distant visual acuity (bUD-VA) using the Greek version of the Early Treatment Diabetic Retinopathy Study Chart at four meters distance~2. Binocular uncorrected reading acuity at 60cm (bUI-RA) and at 40cm (bUN-RA), and~3. Binocular uncorrected critical print size at 60cm (bUI-CPS) and at 40cm (bUN-CPS).~All near and intermediate vision parameters are obtained using the Democritus Digital Acuity Reading Test (DDART), which is based on the Greek version of MNREAD.~Contrast sensitivity are evaluated with the Pelli-Robson test.
Study: NCT00003495

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antineoplaston therapy (Atengenal + Astugenal)
Description: Patients with Stage IV or Recurrent Lung Cancer will receive Antineoplaston therapy (Atengenal + Astugenal).~The daily doses of A10 and AS2-1 are divided into six infusions, which are given at 4-hourly intervals. Each infusion starts with infusion of A10 and is immediately followed by infusion of AS2-1.
Study: NCT03188653

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: CeraVe® Eczema Soothing Body Wash
Description: One of the 7 arm locations will be selected to receive CeraVe® Eczema Soothing Body Wash

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Cetaphil® RestoraDerm® Eczema Calming Body Wash
Description: One of the 7 arm locations will be selected to receive Cetaphil® RestoraDerm® Eczema Calming Body Wash

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Dove® Sensitive Skin Body Wash
Description: One of the 7 arm locations will be selected to receive Dove® Sensitive Skin Body Wash

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Eucerin® Skin Calming Body Wash
Description: One of the 7 arm locations will be selected to receive Eucerin® Skin Calming Body Wash

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Aveeno® Skin Relief Body Wash
Description: One of the 7 arm locations will be selected to receive Aveeno® Skin Relief Body Wash

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: MooGoo® Milk Wash
Description: One of the 7 arm locations will be selected to receive MooGoo® Milk Wash

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Free & Clear Liquid Cleanser
Description: One of the 7 arm locations will be selected to receive Free \& Clear Liquid Cleanser
Study: NCT00513786

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: AUC (area under curve) 5 Intervenous (IV) over 30 minutes given every 21 days for a maximum of 6 cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: 175 mg/m2 over 3 hours given every 21 days for a maximum of 6 cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bevacizumab
Description: 15 mg/kg intervenous (IV) given every 21 days for a maximum of 6 cycles.
Study: NCT04833478

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Anxiety
Description: Techniques used to reduce anxiety in paediatric patients.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Anxiety
Description: Techniques used to reduce anxiety in paediatric patients.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Anxiety
Description: Techniques used to reduce anxiety in paediatric patients.
Study: NCT02132871

Intervention type: DEVICE
Intervention: Impedance cardiography Physioflow ®
Study: NCT02270307

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Dose 50 mg/kg at day +3,+4 once daily

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Mesenchymal stromal cells
Description: Dose 1 million per kg, at day of recovery once
Study: NCT02706249

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Enoxaparin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Enoxaparin